- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04516226
Vaginal Cleansing With Chlorhexidine Gluconate in Women With Preterm Pre-labor Rupture of Membranes
Vaginal Cleansing With Chlorhexidine Gluconate in Women With Preterm Pre-labor Rupture of Membranes in Order to Prolong Pregnancy Latency and Reduce Intraamniotic Inflammation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A randomized controlled trial, including pregnant women > 18 years old with early onset PPROM occurring between the time of peri-viability through the early third trimester (20 weeks 0 days - 33 weeks 0 days) at Albany Medical Center.
Women will be consented by a physician member of the research team on labor and delivery after clinical diagnosis of PPROM. Participation will be completely voluntary and not impact routine prenatal care for PPROM, which may include but not be limited to hospital admission, standard latency antibiotics, NICU consultation, fetal growth ultrasounds, fetal monitoring, and delivery will be based on physician assessment and not impacted by this study. Participation in the study will involve prospective data collection on maternal, fetal, and neonatal characteristics, randomization into a control and treatment group, collection of maternal serum, fetal cord blood and vaginal fluid. Subjects will be randomized into control and treatment groups via block randomization. Exclusions will include any contraindications to expectant management for PPROM noted at the time on admission, such as preterm labor, chorioamnionitis, maternal sepsis and fetal distress.
The time commitment for each subject will include the time from diagnosis of PPROM until their delivery. Although outcome measures will be collected from each neonate, no further participation from subjects will be required after time of their delivery.
Treatment Group: Women diagnosed with PPROM (20 - 33 weeks) randomized to the treatment group will undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of their diagnosis. This specific procedure will only be done once.
The vaginal cleansing procedure will be performed by a single investigator, Dr. Cagino, to ensure consistency. The patient will be examined in dorsal lithotomy position with a standard speculum. A sterile 2x2 gauze placed on ringed forceps will be soaked in sterile 2% chlorhexidine gluconate in
aqueous solution (all available on labor and delivery). Only the rough volume of 2% chlorhexidine gluconate required to soak the small sterile gauze will be used. This soaked gauze will be used to carefully wipe the vaginal mucosa of the vaginal vault. No pooling of chlorhexidine will be left in the vaginal vault. The chlorhexidine solution will not be applied to the cervix or cervical os. The chlorhexidine solution will not be applied directly to the fetus in any way. If a fetal part is visualized at time of exam, the patient will be excluded from the study.
Otherwise, standard care for PPROM among women in this group will not change. This group will be expectantly managed until the time of delivery, which will be based on physician assessment. Delivery decisions for women with preterm labor or infection will be based on physician assessment only and will not be influenced by their involvement in this study.
Control Group: Women diagnosed with PPROM (20 - 33 weeks) randomized to the control group will undergo standard care for PPROM. This group will be expectantly managed until the time of delivery, which will be based on physician assessment. Data will be collected from both the patient and neonate (please see the collection sheet for further information).
Inclusions:
- Pregnant patients at Albany Medical Center with PPROM diagnosed between 20 - 33 weeks
- Age > 18 years old
Exclusions:
- Active preterm labor or imminent delivery expected at time of PPROM diagnosis
- Maternal sepsis or chorioamnionitis diagnosed at time of PPROM diagnosis
- Any contraindications to expectant management at time of PPROM diagnosis (fetal distress, placental abruption with maternal hemodynamic instability or fetal distress, cord prolapse)
- Preeclampsia
- Intrauterine growth restriction (IUGR)
- No antibiotics or steroids given within 7 days prior to time of enrollment/randomization in study (not including steroids or treatment given during admission)
- Multiple gestation
- Placenta previa
- Fetal part visualized at initial exam
- Visual cervical dilation at initial exam
Primary Outcome: Latency (days from PPROM to delivery)
Secondary Outcomes:
- Serum IL6, IL10, TNF-a - admission, day 7, delivery
- Vaginal fluid IL6, IL10, TNF-a - admission, day 7, delivery
- Serial antepartum CBC - admission, day 7, delivery
- Postpartum CBC
- Clinical chorioamnionitis (as defined by treating clinician discretion and requiring treatment with antibiotics and/or delivery)
- Placenta pathology (per pathology lab)
- Histologic chorioamnionitis (based on placental pathology)
Maternal sepsis (as defined by treating clinician discretion)
- Culture proven
- Presumed sepsis
- Composite neonatal morbidity
- Neonatal death
- Fetal demise
A power analysis was performed based on the mean latency of 18 days (SD 10 days) in patients who remained pregnant at least 7 days following PPROM at AMC. In order to detect a prolongation in latency by at least 10 days in the treatment group, an effect size of 1, with a power 0.8 and alpha 0.05, 17 subjects in each study group are needed. A study duration of 1.5 to 2 years to complete enrollment, data collection and analysis is anticipated.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Albany Research Coordinator
- Phone Number: 518-262-4942
- Email: Obgynresearch@amc.edu
Study Locations
-
-
New York
-
Albany, New York, United States, 12208
- Recruiting
- Albany Medical Center
-
Contact:
- Albany research coordinator
- Phone Number: 518-262-4942
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pregnant patients at our institution with PPROM diagnosed between 20 - 33 weeks
Exclusion Criteria:
- active preterm labor or imminent delivery expected at the time of PPROM diagnosis
- maternal sepsis or chorioamnionitis
- any contraindications to expectant management (fetal distress, placental abruption with maternal hemodynamic instability or fetal distress cord prolapse)
- preeclampsia
- intrauterine growth restriction (IUGR)
- no antibiotics or steroids given within 7 days prior to the time of enrollment
- multiple gestation
- placenta previa
- fetal part visualized at initial exam
- visual cervical dilation at initial exam
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaginal cleansing
This group includes patients diagnosed with PPROM that are randomized to undergo vaginal cleansing with chlorhexidine gluconate within 24 hours of PPROM diagnosis.
|
Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
|
No Intervention: No vaginal cleansing
This group includes patients diagnosed with PPROM that are randomized to not undergo vaginal cleansing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy latency
Time Frame: Delivery
|
The time measured in days from the diagnosis of pre labor premature rupture of membranes (PPROM) to delivery.
|
Delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum inflammatory markers
Time Frame: Within 24 hours of admission, 7 days after admission, day of delivery
|
Inflammatory markers from maternal serum including IL6, TNF-a, IL10
|
Within 24 hours of admission, 7 days after admission, day of delivery
|
Amniotic fluid inflammatory markers
Time Frame: Within 24 hours of admission, 7 days after admission, day of delivery
|
Inflammatory markers from amniotic fluid including IL6, TNF-a, IL10
|
Within 24 hours of admission, 7 days after admission, day of delivery
|
White blood cell count, cells per liter
Time Frame: Within 24 hours of admission, 7 days after admission, day of delivery
|
Maternal CBC measured serially antepartum and postpartum
|
Within 24 hours of admission, 7 days after admission, day of delivery
|
Number of participants with clinical chorioamnionitis
Time Frame: Through study completion, an average of 1 year
|
as defined by treating clinical, requiring treatment with antibiotics and/or delivery
|
Through study completion, an average of 1 year
|
Rate of placental abnormalities on pathology evaluation
Time Frame: studied postpartum, up to 1 week
|
Histopathology per pathology lab
|
studied postpartum, up to 1 week
|
Rate of histologic chorioamnionitis
Time Frame: studied postpartum, up to 1 week
|
based on placental pathology
|
studied postpartum, up to 1 week
|
Rate of maternal sepsis
Time Frame: through study completion, up to 1 year
|
as defined by treating clinical, culture proven or presumed
|
through study completion, up to 1 year
|
rate of composite neonatal morbidity
Time Frame: through study completion, up to 1 year
|
culture proven sepsis, respiratory distress, necrotizing enterocolitis, intracranial hemorrhage
|
through study completion, up to 1 year
|
rate of neonatal death
Time Frame: through study completion, up to 1 year
|
demise of neonate
|
through study completion, up to 1 year
|
fetal demise
Time Frame: through study completion, up to 1 year
|
demise of fetus in-utero
|
through study completion, up to 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5743
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preterm Premature Rupture of Membrane
-
Chelsea and Westminster NHS Foundation TrustSPD Development Company Limited; Borne CharityRecruitingPreterm Birth | Preterm Labor | Preterm Birth Complication | Preterm Premature Rupture of Membrane | Preterm PregnancyUnited Kingdom
-
Seoul National University HospitalCompletedPreterm Labor | Preterm Premature Rupture of Membrane (PPROM)Korea, Republic of
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; University College, LondonRecruitingPreterm Birth | Preterm Premature Rupture of Membrane | Preterm Spontaneous Labor With Preterm DeliveryUnited Kingdom
-
Eastern Virginia Medical SchoolNot yet recruitingPreterm Premature Rupture of Membrane
-
Ahmed Mohammed SelimCompleted
-
Albany Medical CollegeRecruitingPreterm Premature Rupture of Membrane | Amniotic Fluid LeakageUnited States
-
University of AarhusMedical University of Graz; Aarhus University Hospital; The University of Texas... and other collaboratorsRecruitingPreterm Birth | Preterm Labor | Preterm Premature Rupture of MembraneDenmark
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
Cairo UniversityCompletedPreterm Premature Rupture of MembraneEgypt
-
Samsung Medical CenterCompletedPreterm Premature Rupture of MembraneKorea, Republic of
Clinical Trials on Vaginal cleansing with chlorhexidine gluconate solution
-
Eunice Kennedy Shriver National Institute of Child...United States Agency for International Development (USAID); Bill and Melinda...CompletedNeonatal MortalityUnited States, Nepal
-
Zagazig UniversityCompletedPostoperative Fever | Wound Infection | Postpartum Endometritis | Chlorhexidine Adverse ReactionSaudi Arabia
-
Angela BiancoStryker NordicTerminatedCesarean Section | Surgical Site Infection | Nosocomial InfectionUnited States
-
The University of Hong KongNot yet recruitingMaternal Infection During Pregnancy
-
Icahn School of Medicine at Mount SinaiCompletedEndometritis | Surgical Site Infections | Infection; Cesarean Section | Chlorhexidine Gluconate Cloths | Infectious MorbidityUnited States
-
University of MilanCompleted
-
Yaneve FongeRecruitingSurgical Site Infection | Cesarean Section; InfectionUnited States
-
Istanbul University - Cerrahpasa (IUC)CompletedSkin Lesion | Catheter-Related Infections | Nursing Caries | Children, Only | Catheter | Disinfectant Dye Adverse Reaction | Chlorhexidine Adverse ReactionTurkey
-
Universidad de GuanajuatoUnknown
-
University of Sao PauloCompletedSurgical Site InfectionBrazil